• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

OccuLogix completes SOLX acquisition

Article

Toronto-OccuLogix Inc. and SOLX Inc. merged in September, with SOLX becoming a wholly owned subsidiary of OccuLogix. Doug Adams, former president and chief executive officer of SOLX, is now president of the subsidiary.

Toronto-OccuLogix Inc. and SOLX Inc. merged in September, with SOLX becoming a wholly owned subsidiary of OccuLogix. Doug Adams, former president and chief executive officer of SOLX, is now president of the subsidiary.

Based at the Boston University Photonics Center, SOLX developed the DeepLight Glaucoma Treatment System, including the DeepLight 790 Titanium Sapphire Laser and the DeepLight Gold Micro-Shunt, which can be used together or separately to reduce IOP. The system components have received international CE approval and are being studied in two randomized, multicenter trials in the United States.

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.